282 related articles for article (PubMed ID: 19274102)
1. Chemical probes that competitively and selectively inhibit Stat3 activation.
Xu X; Kasembeli MM; Jiang X; Tweardy BJ; Tweardy DJ
PLoS One; 2009; 4(3):e4783. PubMed ID: 19274102
[TBL] [Abstract][Full Text] [Related]
2. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
Zhao W; Jaganathan S; Turkson J
J Biol Chem; 2010 Nov; 285(46):35855-65. PubMed ID: 20807764
[TBL] [Abstract][Full Text] [Related]
3. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.
Szelag M; Sikorski K; Czerwoniec A; Szatkowska K; Wesoly J; Bluyssen HA
Eur J Pharmacol; 2013 Nov; 720(1-3):38-48. PubMed ID: 24211327
[TBL] [Abstract][Full Text] [Related]
4. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
[TBL] [Abstract][Full Text] [Related]
5. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer.
Bharadwaj U; Eckols TK; Kolosov M; Kasembeli MM; Adam A; Torres D; Zhang X; Dobrolecki LE; Wei W; Lewis MT; Dave B; Chang JC; Landis MD; Creighton CJ; Mancini MA; Tweardy DJ
Oncogene; 2015 Mar; 34(11):1341-53. PubMed ID: 24681959
[TBL] [Abstract][Full Text] [Related]
6. Novel STAT3 small-molecule inhibitors identified by structure-based virtual ligand screening incorporating SH2 domain flexibility.
Kong R; Bharadwaj U; Eckols TK; Kolosov M; Wu H; Cruz-Pavlovich FJS; Shaw A; Ifelayo OI; Zhao H; Kasembeli MM; Wong STC; Tweardy DJ
Pharmacol Res; 2021 Jul; 169():105637. PubMed ID: 33932608
[TBL] [Abstract][Full Text] [Related]
7. Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins.
Takakuma K; Ogo N; Uehara Y; Takahashi S; Miyoshi N; Asai A
PLoS One; 2013; 8(8):e71646. PubMed ID: 23977103
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a small-molecule inhibitor of STAT3 by ligand-based pharmacophore screening.
Leung KH; Liu LJ; Lin S; Lu L; Zhong HJ; Susanti D; Rao W; Wang M; Che WI; Chan DS; Leung CH; Chan PW; Ma DL
Methods; 2015 Jan; 71():38-43. PubMed ID: 25160651
[TBL] [Abstract][Full Text] [Related]
9. Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.
Bill MA; Nicholas C; Mace TA; Etter JP; Li C; Schwartz EB; Fuchs JR; Young GS; Lin L; Lin J; He L; Phelps M; Li PK; Lesinski GB
PLoS One; 2012; 7(8):e40724. PubMed ID: 22899991
[TBL] [Abstract][Full Text] [Related]
10. Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells.
Liu A; Liu Y; Xu Z; Yu W; Wang H; Li C; Lin J
Cancer Sci; 2011 Jul; 102(7):1381-7. PubMed ID: 21435102
[TBL] [Abstract][Full Text] [Related]
11. Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.
Qiu HY; Zhu X; Luo YL; Lin HY; Tang CY; Qi JL; Pang YJ; Yang RW; Lu GH; Wang XM; Yang YH
Sci Rep; 2017 Jun; 7(1):2863. PubMed ID: 28588262
[TBL] [Abstract][Full Text] [Related]
12. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.
Duan Z; Bradner JE; Greenberg E; Levine R; Foster R; Mahoney J; Seiden MV
Clin Cancer Res; 2006 Nov; 12(22):6844-52. PubMed ID: 17121906
[TBL] [Abstract][Full Text] [Related]
13. Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth.
Li X; Ma H; Li L; Chen Y; Sun X; Dong Z; Liu JY; Zhu W; Zhang JT
Oncogene; 2018 May; 37(18):2469-2480. PubMed ID: 29456240
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
Yu W; Xiao H; Lin J; Li C
J Med Chem; 2013 Jun; 56(11):4402-12. PubMed ID: 23651330
[TBL] [Abstract][Full Text] [Related]
15. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
Duan Z; Bradner J; Greenberg E; Mazitschek R; Foster R; Mahoney J; Seiden MV
Mol Pharmacol; 2007 Nov; 72(5):1137-45. PubMed ID: 17675586
[TBL] [Abstract][Full Text] [Related]
16. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.
Resetca D; Haftchenary S; Gunning PT; Wilson DJ
J Biol Chem; 2014 Nov; 289(47):32538-47. PubMed ID: 25288792
[TBL] [Abstract][Full Text] [Related]
17. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.
Park IH; Li C
J Mol Recognit; 2011; 24(2):254-65. PubMed ID: 21360612
[TBL] [Abstract][Full Text] [Related]
18. Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors.
Cai G; Yu W; Song D; Zhang W; Guo J; Zhu J; Ren Y; Kong L
Eur J Med Chem; 2019 Jul; 174():236-251. PubMed ID: 31048139
[TBL] [Abstract][Full Text] [Related]
19. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization.
Schust J; Sperl B; Hollis A; Mayer TU; Berg T
Chem Biol; 2006 Nov; 13(11):1235-42. PubMed ID: 17114005
[TBL] [Abstract][Full Text] [Related]
20. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
